| Hospital-based costs associated with venous thromboembolism prophylaxis regimens. | |
| | |
MedLine Citation:
|
PMID: 19847624 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Clinically and economically, venous thromboembolic (VTE) disease represents a significant burden to the US healthcare system. This analysis compares the total direct medical costs associated with VTE prophylaxis with enoxaparin and unfractionated heparin (UFH). Hospital discharge and billing records were extracted from the Premier Perspective database (January 2002-December 2006). The primary outcome was the total direct medical costs for discharges that were at risk of VTE and received enoxaparin or UFH. A total of 894,364 discharge records met the study inclusion criteria, of which 39.4% received enoxaparin and 60.6% received UFH. After adjustment for pre-defined covariates, mean total direct medical costs per discharge for the UFH group were $6,443, $1,080 more than those for the enoxaparin group ($5,363; P < .0001). In conclusion, enoxaparin prophylaxis is a cost-saving therapy, when compared with UFH, for the prevention of VTE in patients with a diverse range of medical conditions conferring VTE risk. |
| | |
Authors:
|
Geno Merli; Cheryl P Ferrufino; Jay Lin; Mohammed Hussein; David Battleman |
Related Documents
:
|
10623014 - Alternative to pcs nets medical group nearly $200,000 annual savings. 8775524 - Cost-effectiveness of coronary angioplasty versus medical treatment: the impact of cost... 19329774 - Incorporating extrinsic goals into decision and cost-effectiveness analyses. 7737444 - Enhancing compliance with screening mammography recommendations: a clinical trial in a ... 18977954 - Trends in the prevalence of chronic medication use in children: 2002-2005. 12959344 - Morphometry of auricular feathers of barn owls (tyto alba). |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of thrombosis and thrombolysis Volume: 29 ISSN: 1573-742X ISO Abbreviation: J. Thromb. Thrombolysis Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-05-10 Completed Date: 2010-08-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9502018 Medline TA: J Thromb Thrombolysis Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 449-58 Citation Subset: IM |
Affiliation:
|
Jefferson Vascular Diseases Center, Jefferson Medical College, Thomas Jefferson University Hospital, Suite 6250, Philadelphia, PA 19107, USA. geno.merli@jefferson.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Anticoagulants / administration & dosage*, economics* Costs and Cost Analysis Databases, Factual Enoxaparin / administration & dosage*, economics* Female Humans Male Middle Aged Retrospective Studies Risk Factors Venous Thromboembolism / economics*, prevention & control* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Enoxaparin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The invasiveness of five medulloblastoma cell lines in collagen gels.
Next Document: Heat denatured/aggregated albumin-based biomaterial: effects of preparation parameters on biodegrada...